ArticlePLoS neglected tropical diseases2026
Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal.PLoS neglected tropical diseases · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile typhoid conjugate vaccines (TCV) offer promise for reducing risk in endemic settings, their population-level impact remains unclear. In 2022, Nepal introduced TCV nationally on the heels of the COVID-19 pandemic, which disrupted healthcare services, surveillance, and potentially typhoid transmission dynamics, complicating vaccine impact evaluation. We investigated the impact of TCV introduction amid shifting typhoid burden during the pandemic.
methodsWe analyzed blood culture data from four Kathmandu Valley health facilities, comparing culture positivity for Salmonella Typhi across three periods: pre-pandemic (January 2018-March 2020); pandemic, pre-vaccine introduction (April 2020-March 2022); post-vaccine introduction (April 2022-April 2024). We used multivariable logistic regression to assess S. Typhi positivity, adjusting for month and site, stratified by TCV-eligible children and older, TCV-ineligible populations.
resultsBetween January 2018 and April 2024, 62,236 blood cultures were performed. S. Typhi blood culture positivity decreased from 2.11% pre-pandemic to 0.59% during the pandemic (p < 0.001) and remained low at 0.69% after TCV introduction. Among TCV-eligible children (15 months to 15 years), odds of S. Typhi positivity during the pandemic were 47% lower than the pre-COVID period (aOR 0.53, 95% CI 0.29-0.90) and continued to decrease by 75% post-TCV introduction (aOR 0.25, 95% CI 0.11-0.55). In contrast, among vaccine-ineligible individuals (≥16 years), odds of positivity during the pandemic were 77% lower than the pre-COVID period (aOR 0.23, 95% CI 0.16-0.31) but increased by 59% following TCV rollout (aOR 1.59, 95% CI 1.14-2.27). Sensitivity analyses restricted to pathogen-positive cultures yielded similar results.
conclusionS. Typhi blood culture positivity declined sharply during the pandemic before TCV introduction. The subsequent rollout of TCV substantially reduced typhoid burden in vaccine-eligible children; however, rising cases among older, vaccine-ineligible populations following the relaxation of pandemic measures highlights the need for additional control measures such as improved water and sanitation infrastructure and broader age eligibility for typhoid vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.